PharmChem, Inc.
PharmChem, Inc. (PCHM) Stock Competitors & Peer Comparison
See (PCHM) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PCHM | $3.75 | +0.27% | 22M | -0.02 | -$212.50 | N/A |
| LZAGF | $650.49 | -3.66% | 46.8B | 40.00 | $16.67 | +0.37% |
| LZAGY | $63.43 | -1.84% | 46.4B | 39.30 | $1.66 | +0.67% |
| WUXAY | $15.60 | +2.63% | 43.7B | 15.76 | $0.97 | +1.20% |
| WUXIF | $13.88 | +0.00% | 41.4B | 14.31 | $0.97 | +1.68% |
| ERFSF | $73.82 | -10.51% | 12.9B | 24.53 | $3.01 | +0.83% |
| BMXMF | $105.41 | +0.00% | 12.4B | 26.75 | $3.94 | +0.89% |
| SKHHY | $14.40 | +1.34% | 7.1B | 18.19 | $0.79 | +2.24% |
| SKHCF | $14.30 | -1.89% | 6.5B | 17.91 | $0.74 | +2.18% |
| HNGZY | $4.00 | +0.00% | 6.2B | 26.67 | $0.15 | +0.72% |
Stock Comparison
PCHM vs LZAGF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, LZAGF has a market cap of 46.8B. Regarding current trading prices, PCHM is priced at $3.75, while LZAGF trades at $650.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas LZAGF's P/E ratio is 40.00. In terms of profitability, PCHM's ROE is +0.25%, compared to LZAGF's ROE of +0.10%. Regarding short-term risk, PCHM is less volatile compared to LZAGF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check LZAGF's competition here
PCHM vs LZAGY Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, LZAGY has a market cap of 46.4B. Regarding current trading prices, PCHM is priced at $3.75, while LZAGY trades at $63.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas LZAGY's P/E ratio is 39.30. In terms of profitability, PCHM's ROE is +0.25%, compared to LZAGY's ROE of +0.10%. Regarding short-term risk, PCHM is less volatile compared to LZAGY. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check LZAGY's competition here
PCHM vs WUXAY Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, WUXAY has a market cap of 43.7B. Regarding current trading prices, PCHM is priced at $3.75, while WUXAY trades at $15.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas WUXAY's P/E ratio is 15.76. In terms of profitability, PCHM's ROE is +0.25%, compared to WUXAY's ROE of +0.28%. Regarding short-term risk, PCHM is more volatile compared to WUXAY. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check WUXAY's competition here
PCHM vs WUXIF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, WUXIF has a market cap of 41.4B. Regarding current trading prices, PCHM is priced at $3.75, while WUXIF trades at $13.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas WUXIF's P/E ratio is 14.31. In terms of profitability, PCHM's ROE is +0.25%, compared to WUXIF's ROE of +0.28%. Regarding short-term risk, PCHM is less volatile compared to WUXIF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check WUXIF's competition here
PCHM vs ERFSF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, ERFSF has a market cap of 12.9B. Regarding current trading prices, PCHM is priced at $3.75, while ERFSF trades at $73.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas ERFSF's P/E ratio is 24.53. In terms of profitability, PCHM's ROE is +0.25%, compared to ERFSF's ROE of +0.12%. Regarding short-term risk, PCHM is less volatile compared to ERFSF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check ERFSF's competition here
PCHM vs BMXMF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, BMXMF has a market cap of 12.4B. Regarding current trading prices, PCHM is priced at $3.75, while BMXMF trades at $105.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas BMXMF's P/E ratio is 26.75. In terms of profitability, PCHM's ROE is +0.25%, compared to BMXMF's ROE of +0.10%. Regarding short-term risk, PCHM is less volatile compared to BMXMF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check BMXMF's competition here
PCHM vs SKHHY Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, SKHHY has a market cap of 7.1B. Regarding current trading prices, PCHM is priced at $3.75, while SKHHY trades at $14.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas SKHHY's P/E ratio is 18.19. In terms of profitability, PCHM's ROE is +0.25%, compared to SKHHY's ROE of +0.05%. Regarding short-term risk, PCHM is more volatile compared to SKHHY. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check SKHHY's competition here
PCHM vs SKHCF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, SKHCF has a market cap of 6.5B. Regarding current trading prices, PCHM is priced at $3.75, while SKHCF trades at $14.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas SKHCF's P/E ratio is 17.91. In terms of profitability, PCHM's ROE is +0.25%, compared to SKHCF's ROE of +0.06%. Regarding short-term risk, PCHM is less volatile compared to SKHCF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check SKHCF's competition here
PCHM vs HNGZY Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, HNGZY has a market cap of 6.2B. Regarding current trading prices, PCHM is priced at $3.75, while HNGZY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas HNGZY's P/E ratio is 26.67. In terms of profitability, PCHM's ROE is +0.25%, compared to HNGZY's ROE of +0.04%. Regarding short-term risk, PCHM is less volatile compared to HNGZY. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check HNGZY's competition here
PCHM vs DSRLF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, DSRLF has a market cap of 3.9B. Regarding current trading prices, PCHM is priced at $3.75, while DSRLF trades at $71.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas DSRLF's P/E ratio is 21.47. In terms of profitability, PCHM's ROE is +0.25%, compared to DSRLF's ROE of +0.12%. Regarding short-term risk, PCHM is less volatile compared to DSRLF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check DSRLF's competition here
PCHM vs VIMGF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, VIMGF has a market cap of 1.5B. Regarding current trading prices, PCHM is priced at $3.75, while VIMGF trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas VIMGF's P/E ratio is 39.57. In terms of profitability, PCHM's ROE is +0.25%, compared to VIMGF's ROE of +0.05%. Regarding short-term risk, PCHM is less volatile compared to VIMGF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check VIMGF's competition here
PCHM vs GNTLF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, GNTLF has a market cap of 1.3B. Regarding current trading prices, PCHM is priced at $3.75, while GNTLF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas GNTLF's P/E ratio is -16.67. In terms of profitability, PCHM's ROE is +0.25%, compared to GNTLF's ROE of -1.85%. Regarding short-term risk, PCHM is more volatile compared to GNTLF. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check GNTLF's competition here
PCHM vs MRCHF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, MRCHF has a market cap of 1.1B. Regarding current trading prices, PCHM is priced at $3.75, while MRCHF trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas MRCHF's P/E ratio is 44.29. In terms of profitability, PCHM's ROE is +0.25%, compared to MRCHF's ROE of +0.04%. Regarding short-term risk, PCHM is more volatile compared to MRCHF. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check MRCHF's competition here
PCHM vs IDGXF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, IDGXF has a market cap of 372M. Regarding current trading prices, PCHM is priced at $3.75, while IDGXF trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas IDGXF's P/E ratio is 16.00. In terms of profitability, PCHM's ROE is +0.25%, compared to IDGXF's ROE of +0.28%. Regarding short-term risk, PCHM is less volatile compared to IDGXF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check IDGXF's competition here
PCHM vs EDTXF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, EDTXF has a market cap of 297.9M. Regarding current trading prices, PCHM is priced at $3.75, while EDTXF trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas EDTXF's P/E ratio is -8.46. In terms of profitability, PCHM's ROE is +0.25%, compared to EDTXF's ROE of +0.88%. Regarding short-term risk, PCHM is more volatile compared to EDTXF. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check EDTXF's competition here
PCHM vs AMCY Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, AMCY has a market cap of 171.3M. Regarding current trading prices, PCHM is priced at $3.75, while AMCY trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas AMCY's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to AMCY's ROE of N/A. Regarding short-term risk, PCHM is more volatile compared to AMCY. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check AMCY's competition here
PCHM vs NNGRF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, NNGRF has a market cap of 164.3M. Regarding current trading prices, PCHM is priced at $3.75, while NNGRF trades at $12.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas NNGRF's P/E ratio is 60.75. In terms of profitability, PCHM's ROE is +0.25%, compared to NNGRF's ROE of -0.05%. Regarding short-term risk, PCHM is more volatile compared to NNGRF. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check NNGRF's competition here
PCHM vs DIUXF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, DIUXF has a market cap of 141.3M. Regarding current trading prices, PCHM is priced at $3.75, while DIUXF trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas DIUXF's P/E ratio is -83.50. In terms of profitability, PCHM's ROE is +0.25%, compared to DIUXF's ROE of -0.04%. Regarding short-term risk, PCHM is less volatile compared to DIUXF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check DIUXF's competition here
PCHM vs CORBF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, CORBF has a market cap of 127.2M. Regarding current trading prices, PCHM is priced at $3.75, while CORBF trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas CORBF's P/E ratio is 2.71. In terms of profitability, PCHM's ROE is +0.25%, compared to CORBF's ROE of +0.11%. Regarding short-term risk, PCHM is more volatile compared to CORBF. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check CORBF's competition here
PCHM vs LDXHF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, LDXHF has a market cap of 106.9M. Regarding current trading prices, PCHM is priced at $3.75, while LDXHF trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas LDXHF's P/E ratio is -14.00. In terms of profitability, PCHM's ROE is +0.25%, compared to LDXHF's ROE of -1.21%. Regarding short-term risk, PCHM is less volatile compared to LDXHF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check LDXHF's competition here
PCHM vs THOXF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, THOXF has a market cap of 73.8M. Regarding current trading prices, PCHM is priced at $3.75, while THOXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas THOXF's P/E ratio is -7.45. In terms of profitability, PCHM's ROE is +0.25%, compared to THOXF's ROE of -1.67%. Regarding short-term risk, PCHM is less volatile compared to THOXF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check THOXF's competition here
PCHM vs TIHE Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, TIHE has a market cap of 71.9M. Regarding current trading prices, PCHM is priced at $3.75, while TIHE trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas TIHE's P/E ratio is 0.32. In terms of profitability, PCHM's ROE is +0.25%, compared to TIHE's ROE of +0.01%. Regarding short-term risk, PCHM is more volatile compared to TIHE. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check TIHE's competition here
PCHM vs PFGTF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, PFGTF has a market cap of 69.8M. Regarding current trading prices, PCHM is priced at $3.75, while PFGTF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas PFGTF's P/E ratio is -3.41. In terms of profitability, PCHM's ROE is +0.25%, compared to PFGTF's ROE of -1.30%. Regarding short-term risk, PCHM is less volatile compared to PFGTF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check PFGTF's competition here
PCHM vs BIOGF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, BIOGF has a market cap of 65.4M. Regarding current trading prices, PCHM is priced at $3.75, while BIOGF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas BIOGF's P/E ratio is -0.67. In terms of profitability, PCHM's ROE is +0.25%, compared to BIOGF's ROE of +2.04%. Regarding short-term risk, PCHM is more volatile compared to BIOGF. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check BIOGF's competition here
PCHM vs PCNEF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, PCNEF has a market cap of 62M. Regarding current trading prices, PCHM is priced at $3.75, while PCNEF trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas PCNEF's P/E ratio is -8.44. In terms of profitability, PCHM's ROE is +0.25%, compared to PCNEF's ROE of -0.05%. Regarding short-term risk, PCHM is less volatile compared to PCNEF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check PCNEF's competition here
PCHM vs BMKDF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, BMKDF has a market cap of 44.5M. Regarding current trading prices, PCHM is priced at $3.75, while BMKDF trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas BMKDF's P/E ratio is -42.38. In terms of profitability, PCHM's ROE is +0.25%, compared to BMKDF's ROE of -1.53%. Regarding short-term risk, PCHM is less volatile compared to BMKDF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check BMKDF's competition here
PCHM vs BIOQ Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, BIOQ has a market cap of 33.5M. Regarding current trading prices, PCHM is priced at $3.75, while BIOQ trades at $37.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas BIOQ's P/E ratio is 15.83. In terms of profitability, PCHM's ROE is +0.25%, compared to BIOQ's ROE of +0.01%. Regarding short-term risk, PCHM is less volatile compared to BIOQ. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check BIOQ's competition here
PCHM vs SNANF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, SNANF has a market cap of 27M. Regarding current trading prices, PCHM is priced at $3.75, while SNANF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas SNANF's P/E ratio is -11.80. In terms of profitability, PCHM's ROE is +0.25%, compared to SNANF's ROE of -10.44%. Regarding short-term risk, PCHM is less volatile compared to SNANF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check SNANF's competition here
PCHM vs ANPCY Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, ANPCY has a market cap of 22M. Regarding current trading prices, PCHM is priced at $3.75, while ANPCY trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas ANPCY's P/E ratio is -0.10. In terms of profitability, PCHM's ROE is +0.25%, compared to ANPCY's ROE of -0.90%. Regarding short-term risk, PCHM is less volatile compared to ANPCY. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check ANPCY's competition here
PCHM vs VILGF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, VILGF has a market cap of 20.7M. Regarding current trading prices, PCHM is priced at $3.75, while VILGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas VILGF's P/E ratio is -0.30. In terms of profitability, PCHM's ROE is +0.25%, compared to VILGF's ROE of N/A. Regarding short-term risk, PCHM is more volatile compared to VILGF. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check VILGF's competition here
PCHM vs CLIFF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, CLIFF has a market cap of 18M. Regarding current trading prices, PCHM is priced at $3.75, while CLIFF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas CLIFF's P/E ratio is -1.76. In terms of profitability, PCHM's ROE is +0.25%, compared to CLIFF's ROE of -0.12%. Regarding short-term risk, PCHM is less volatile compared to CLIFF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check CLIFF's competition here
PCHM vs LDDD Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, LDDD has a market cap of 15.3M. Regarding current trading prices, PCHM is priced at $3.75, while LDDD trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas LDDD's P/E ratio is -51.00. In terms of profitability, PCHM's ROE is +0.25%, compared to LDDD's ROE of -0.28%. Regarding short-term risk, PCHM is less volatile compared to LDDD. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check LDDD's competition here
PCHM vs IZOZF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, IZOZF has a market cap of 14.5M. Regarding current trading prices, PCHM is priced at $3.75, while IZOZF trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas IZOZF's P/E ratio is -10.50. In terms of profitability, PCHM's ROE is +0.25%, compared to IZOZF's ROE of +0.48%. Regarding short-term risk, PCHM is less volatile compared to IZOZF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check IZOZF's competition here
PCHM vs ABDXF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, ABDXF has a market cap of 13.3M. Regarding current trading prices, PCHM is priced at $3.75, while ABDXF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas ABDXF's P/E ratio is -1.40. In terms of profitability, PCHM's ROE is +0.25%, compared to ABDXF's ROE of -0.45%. Regarding short-term risk, PCHM is more volatile compared to ABDXF. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check ABDXF's competition here
PCHM vs IDXG Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, IDXG has a market cap of 8.8M. Regarding current trading prices, PCHM is priced at $3.75, while IDXG trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas IDXG's P/E ratio is 2.22. In terms of profitability, PCHM's ROE is +0.25%, compared to IDXG's ROE of +4.85%. Regarding short-term risk, PCHM is less volatile compared to IDXG. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check IDXG's competition here
PCHM vs MXDHF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, MXDHF has a market cap of 8.6M. Regarding current trading prices, PCHM is priced at $3.75, while MXDHF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas MXDHF's P/E ratio is -0.12. In terms of profitability, PCHM's ROE is +0.25%, compared to MXDHF's ROE of +5.17%. Regarding short-term risk, PCHM is more volatile compared to MXDHF. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check MXDHF's competition here
PCHM vs JMPHF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, JMPHF has a market cap of 8.1M. Regarding current trading prices, PCHM is priced at $3.75, while JMPHF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas JMPHF's P/E ratio is 4.28. In terms of profitability, PCHM's ROE is +0.25%, compared to JMPHF's ROE of +0.31%. Regarding short-term risk, PCHM is less volatile compared to JMPHF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check JMPHF's competition here
PCHM vs ICBU Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, ICBU has a market cap of 6.1M. Regarding current trading prices, PCHM is priced at $3.75, while ICBU trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas ICBU's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to ICBU's ROE of -0.22%. Regarding short-term risk, PCHM is more volatile compared to ICBU. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check ICBU's competition here
PCHM vs IMMVF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, IMMVF has a market cap of 6.1M. Regarding current trading prices, PCHM is priced at $3.75, while IMMVF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas IMMVF's P/E ratio is -0.50. In terms of profitability, PCHM's ROE is +0.25%, compared to IMMVF's ROE of -5.64%. Regarding short-term risk, PCHM is less volatile compared to IMMVF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check IMMVF's competition here
PCHM vs SQIDF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, SQIDF has a market cap of 6.1M. Regarding current trading prices, PCHM is priced at $3.75, while SQIDF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas SQIDF's P/E ratio is -0.37. In terms of profitability, PCHM's ROE is +0.25%, compared to SQIDF's ROE of +4.47%. Regarding short-term risk, PCHM is less volatile compared to SQIDF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check SQIDF's competition here
PCHM vs PMSNF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, PMSNF has a market cap of 5.2M. Regarding current trading prices, PCHM is priced at $3.75, while PMSNF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas PMSNF's P/E ratio is -1.00. In terms of profitability, PCHM's ROE is +0.25%, compared to PMSNF's ROE of +0.34%. Regarding short-term risk, PCHM is more volatile compared to PMSNF. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check PMSNF's competition here
PCHM vs AVCRF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, AVCRF has a market cap of 4.9M. Regarding current trading prices, PCHM is priced at $3.75, while AVCRF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas AVCRF's P/E ratio is -4.80. In terms of profitability, PCHM's ROE is +0.25%, compared to AVCRF's ROE of -0.95%. Regarding short-term risk, PCHM is less volatile compared to AVCRF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check AVCRF's competition here
PCHM vs VRCDF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, VRCDF has a market cap of 4.5M. Regarding current trading prices, PCHM is priced at $3.75, while VRCDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas VRCDF's P/E ratio is -0.10. In terms of profitability, PCHM's ROE is +0.25%, compared to VRCDF's ROE of -1.93%. Regarding short-term risk, PCHM is less volatile compared to VRCDF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check VRCDF's competition here
PCHM vs RNVA Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, RNVA has a market cap of 4.3M. Regarding current trading prices, PCHM is priced at $3.75, while RNVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas RNVA's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to RNVA's ROE of +0.23%. Regarding short-term risk, PCHM is more volatile compared to RNVA. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check RNVA's competition here
PCHM vs TDSGF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, TDSGF has a market cap of 4M. Regarding current trading prices, PCHM is priced at $3.75, while TDSGF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas TDSGF's P/E ratio is -3.94. In terms of profitability, PCHM's ROE is +0.25%, compared to TDSGF's ROE of -9.19%. Regarding short-term risk, PCHM is more volatile compared to TDSGF. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check TDSGF's competition here
PCHM vs ANPCF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, ANPCF has a market cap of 3.4M. Regarding current trading prices, PCHM is priced at $3.75, while ANPCF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas ANPCF's P/E ratio is -0.17. In terms of profitability, PCHM's ROE is +0.25%, compared to ANPCF's ROE of -0.90%. Regarding short-term risk, PCHM is less volatile compared to ANPCF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check ANPCF's competition here
PCHM vs IBXXF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, IBXXF has a market cap of 2.2M. Regarding current trading prices, PCHM is priced at $3.75, while IBXXF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas IBXXF's P/E ratio is -1.00. In terms of profitability, PCHM's ROE is +0.25%, compared to IBXXF's ROE of +1.43%. Regarding short-term risk, PCHM is less volatile compared to IBXXF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check IBXXF's competition here
PCHM vs IVRO Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, IVRO has a market cap of 1.8M. Regarding current trading prices, PCHM is priced at $3.75, while IVRO trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas IVRO's P/E ratio is -0.80. In terms of profitability, PCHM's ROE is +0.25%, compared to IVRO's ROE of +0.06%. Regarding short-term risk, PCHM is more volatile compared to IVRO. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check IVRO's competition here
PCHM vs CHHL Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, CHHL has a market cap of 1.8M. Regarding current trading prices, PCHM is priced at $3.75, while CHHL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas CHHL's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to CHHL's ROE of +0.00%. Regarding short-term risk, PCHM is less volatile compared to CHHL. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check CHHL's competition here
PCHM vs SLDX Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, SLDX has a market cap of 1.6M. Regarding current trading prices, PCHM is priced at $3.75, while SLDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas SLDX's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to SLDX's ROE of +0.17%. Regarding short-term risk, PCHM is less volatile compared to SLDX. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check SLDX's competition here
PCHM vs DIGP Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, DIGP has a market cap of 1.1M. Regarding current trading prices, PCHM is priced at $3.75, while DIGP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas DIGP's P/E ratio is -1.04. In terms of profitability, PCHM's ROE is +0.25%, compared to DIGP's ROE of +1.19%. Regarding short-term risk, PCHM is less volatile compared to DIGP. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check DIGP's competition here
PCHM vs EPGNF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, EPGNF has a market cap of 982.2K. Regarding current trading prices, PCHM is priced at $3.75, while EPGNF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas EPGNF's P/E ratio is -0.30. In terms of profitability, PCHM's ROE is +0.25%, compared to EPGNF's ROE of +0.03%. Regarding short-term risk, PCHM is more volatile compared to EPGNF. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check EPGNF's competition here
PCHM vs RSHN Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, RSHN has a market cap of 857.6K. Regarding current trading prices, PCHM is priced at $3.75, while RSHN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas RSHN's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to RSHN's ROE of -5.42%. Regarding short-term risk, PCHM is more volatile compared to RSHN. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check RSHN's competition here
PCHM vs IDTA Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, IDTA has a market cap of 708K. Regarding current trading prices, PCHM is priced at $3.75, while IDTA trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas IDTA's P/E ratio is 8.75. In terms of profitability, PCHM's ROE is +0.25%, compared to IDTA's ROE of +0.13%. Regarding short-term risk, PCHM is more volatile compared to IDTA. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check IDTA's competition here
PCHM vs SZLSF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, SZLSF has a market cap of 630K. Regarding current trading prices, PCHM is priced at $3.75, while SZLSF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas SZLSF's P/E ratio is -0.04. In terms of profitability, PCHM's ROE is +0.25%, compared to SZLSF's ROE of +4.82%. Regarding short-term risk, PCHM is less volatile compared to SZLSF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check SZLSF's competition here
PCHM vs SCRSF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, SCRSF has a market cap of 600.3K. Regarding current trading prices, PCHM is priced at $3.75, while SCRSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas SCRSF's P/E ratio is -0.20. In terms of profitability, PCHM's ROE is +0.25%, compared to SCRSF's ROE of +2.02%. Regarding short-term risk, PCHM is more volatile compared to SCRSF. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check SCRSF's competition here
PCHM vs NSTM Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, NSTM has a market cap of 493.3K. Regarding current trading prices, PCHM is priced at $3.75, while NSTM trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas NSTM's P/E ratio is 0.20. In terms of profitability, PCHM's ROE is +0.25%, compared to NSTM's ROE of -0.83%. Regarding short-term risk, PCHM is less volatile compared to NSTM. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check NSTM's competition here
PCHM vs MBGNF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, MBGNF has a market cap of 101.8K. Regarding current trading prices, PCHM is priced at $3.75, while MBGNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas MBGNF's P/E ratio is -0.59. In terms of profitability, PCHM's ROE is +0.25%, compared to MBGNF's ROE of +0.26%. Regarding short-term risk, PCHM is less volatile compared to MBGNF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check MBGNF's competition here
PCHM vs NVTAQ Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, NVTAQ has a market cap of 85.9K. Regarding current trading prices, PCHM is priced at $3.75, while NVTAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas NVTAQ's P/E ratio is -0.00. In terms of profitability, PCHM's ROE is +0.25%, compared to NVTAQ's ROE of +0.00%. Regarding short-term risk, PCHM is less volatile compared to NVTAQ. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check NVTAQ's competition here
PCHM vs ARYC Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, ARYC has a market cap of 79.3K. Regarding current trading prices, PCHM is priced at $3.75, while ARYC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas ARYC's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to ARYC's ROE of +0.55%. Regarding short-term risk, PCHM is less volatile compared to ARYC. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check ARYC's competition here
PCHM vs HCLC Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, HCLC has a market cap of 74K. Regarding current trading prices, PCHM is priced at $3.75, while HCLC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas HCLC's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to HCLC's ROE of +0.11%. Regarding short-term risk, PCHM is more volatile compared to HCLC. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check HCLC's competition here
PCHM vs MEDD Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, MEDD has a market cap of 63.8K. Regarding current trading prices, PCHM is priced at $3.75, while MEDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas MEDD's P/E ratio is -0.02. In terms of profitability, PCHM's ROE is +0.25%, compared to MEDD's ROE of +0.74%. Regarding short-term risk, PCHM is less volatile compared to MEDD. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check MEDD's competition here
PCHM vs IHTI Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, IHTI has a market cap of 32.5K. Regarding current trading prices, PCHM is priced at $3.75, while IHTI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas IHTI's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to IHTI's ROE of +0.00%. Regarding short-term risk, PCHM is less volatile compared to IHTI. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check IHTI's competition here
PCHM vs TOMDF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, TOMDF has a market cap of 14.1K. Regarding current trading prices, PCHM is priced at $3.75, while TOMDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas TOMDF's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to TOMDF's ROE of +0.84%. Regarding short-term risk, PCHM is less volatile compared to TOMDF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check TOMDF's competition here
PCHM vs CGNH Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, CGNH has a market cap of 12K. Regarding current trading prices, PCHM is priced at $3.75, while CGNH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas CGNH's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to CGNH's ROE of +1.41%. Regarding short-term risk, PCHM is more volatile compared to CGNH. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check CGNH's competition here
PCHM vs ABMC Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, ABMC has a market cap of 4.8K. Regarding current trading prices, PCHM is priced at $3.75, while ABMC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas ABMC's P/E ratio is 0.01. In terms of profitability, PCHM's ROE is +0.25%, compared to ABMC's ROE of +0.86%. Regarding short-term risk, PCHM is more volatile compared to ABMC. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check ABMC's competition here
PCHM vs CYPS Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, CYPS has a market cap of 4.1K. Regarding current trading prices, PCHM is priced at $3.75, while CYPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas CYPS's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to CYPS's ROE of N/A. Regarding short-term risk, PCHM is more volatile compared to CYPS. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check CYPS's competition here
PCHM vs RGDXQ Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, RGDXQ has a market cap of 3.9K. Regarding current trading prices, PCHM is priced at $3.75, while RGDXQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas RGDXQ's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to RGDXQ's ROE of -1.27%. Regarding short-term risk, PCHM is less volatile compared to RGDXQ. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check RGDXQ's competition here
PCHM vs DMTKQ Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, DMTKQ has a market cap of 3.5K. Regarding current trading prices, PCHM is priced at $3.75, while DMTKQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas DMTKQ's P/E ratio is -0.00. In terms of profitability, PCHM's ROE is +0.25%, compared to DMTKQ's ROE of -1.06%. Regarding short-term risk, PCHM is more volatile compared to DMTKQ. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check DMTKQ's competition here
PCHM vs MEDVF Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, MEDVF has a market cap of 2.7K. Regarding current trading prices, PCHM is priced at $3.75, while MEDVF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas MEDVF's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to MEDVF's ROE of +2.13%. Regarding short-term risk, PCHM is less volatile compared to MEDVF. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check MEDVF's competition here
PCHM vs GWHP Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, GWHP has a market cap of 1.3K. Regarding current trading prices, PCHM is priced at $3.75, while GWHP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas GWHP's P/E ratio is -0.00. In terms of profitability, PCHM's ROE is +0.25%, compared to GWHP's ROE of +6.19%. Regarding short-term risk, PCHM is less volatile compared to GWHP. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check GWHP's competition here
PCHM vs ROSGQ Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, ROSGQ has a market cap of 593. Regarding current trading prices, PCHM is priced at $3.75, while ROSGQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas ROSGQ's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to ROSGQ's ROE of -1.35%. Regarding short-term risk, PCHM is more volatile compared to ROSGQ. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check ROSGQ's competition here
PCHM vs BIOCQ Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, BIOCQ has a market cap of 263. Regarding current trading prices, PCHM is priced at $3.75, while BIOCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas BIOCQ's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to BIOCQ's ROE of -1.38%. Regarding short-term risk, PCHM is more volatile compared to BIOCQ. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check BIOCQ's competition here
PCHM vs HTGMQ Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, HTGMQ has a market cap of 221. Regarding current trading prices, PCHM is priced at $3.75, while HTGMQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas HTGMQ's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to HTGMQ's ROE of -2.73%. Regarding short-term risk, PCHM is more volatile compared to HTGMQ. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check HTGMQ's competition here
PCHM vs OPGX Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, OPGX has a market cap of 17. Regarding current trading prices, PCHM is priced at $3.75, while OPGX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas OPGX's P/E ratio is -0.00. In terms of profitability, PCHM's ROE is +0.25%, compared to OPGX's ROE of +0.46%. Regarding short-term risk, PCHM is less volatile compared to OPGX. This indicates potentially lower risk in terms of short-term price fluctuations for PCHM.Check OPGX's competition here
PCHM vs MRPS Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, MRPS has a market cap of 0. Regarding current trading prices, PCHM is priced at $3.75, while MRPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas MRPS's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to MRPS's ROE of N/A. Regarding short-term risk, PCHM is more volatile compared to MRPS. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check MRPS's competition here
PCHM vs AGHC Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, AGHC has a market cap of 0. Regarding current trading prices, PCHM is priced at $3.75, while AGHC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas AGHC's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to AGHC's ROE of +2.90%. Regarding short-term risk, PCHM is more volatile compared to AGHC. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check AGHC's competition here
PCHM vs EPGNY Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, EPGNY has a market cap of 0. Regarding current trading prices, PCHM is priced at $3.75, while EPGNY trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas EPGNY's P/E ratio is -1.60. In terms of profitability, PCHM's ROE is +0.25%, compared to EPGNY's ROE of -0.19%. Regarding short-term risk, PCHM is more volatile compared to EPGNY. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check EPGNY's competition here
PCHM vs BGNX Comparison April 2026
PCHM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCHM stands at 22M. In comparison, BGNX has a market cap of 0. Regarding current trading prices, PCHM is priced at $3.75, while BGNX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCHM currently has a P/E ratio of -0.02, whereas BGNX's P/E ratio is N/A. In terms of profitability, PCHM's ROE is +0.25%, compared to BGNX's ROE of N/A. Regarding short-term risk, PCHM is more volatile compared to BGNX. This indicates potentially higher risk in terms of short-term price fluctuations for PCHM.Check BGNX's competition here